Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | FLT1 | P17948 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 4/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CSK | P41240 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612797 | 0.89 | FGFR4 (0.62) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL15434030 | 0.86 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3FLT1 | |
| SCHEMBL16072052 | 0.84 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3MAPK3 | |
| SCHEMBL24690432 | 0.81 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3MAPK3 | |
| SCHEMBL23314947 | 0.79 | FGFR4 (0.88) | FGFR4FGFR1FGFR2FGFR3FLT1 | |
| SCHEMBL2348899 | 0.78 | FGFR1 (0.62) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL15434011 | 0.77 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL31648262 | 0.76 | FGFR1 (0.76) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL1248489 | 0.76 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL29366761 | 0.76 | FGFR1 (1.00) | FGFR4FGFR1FGFR2FGFR3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126951-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.